---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-021512"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:30:14.560232+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics enters ATM agreement with H.C. Wainwright for up to $5.14M in common stock

## Summary
- Entered ATM agreement with H.C. Wainwright to sell up to $5,143,730 of common stock from time to time.
- Sales agent compensation is 3.0% of gross proceeds; no minimum sale obligation.
- Offering subject to effectiveness of Form S-3 registration statement filed March 11, 2024.
- Company can terminate agreement at any time; Wainwright can terminate on material adverse change.

## SEC filing metadata
- accession: 0001213900-24-021512
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/0001213900-24-021512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/ea0201524-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-021512
- JSON: https://secwatch.observer/filing/0001213900-24-021512.json
- Plain text: https://secwatch.observer/filing/0001213900-24-021512.txt

## Key facts
- Material Agreements
  Cadrenal Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at $5,143,730 (effective 2024-03-11).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: $5,143,730
  - Effective: 2024-03-11
  source text: On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation, (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/0001213900-24-021512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.